Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06453694 · ClinicalTrials.gov registry record · Phase 2
Efgartigimod for the Treatment of Acute Optic Neuritis
A Phase 2 study of Optic Neuritis, sponsored by Anastasia Vishnevetsky, MD, MPH.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT06453694 is a Phase 2 study of Optic Neuritis that is actively recruiting participants, run by Anastasia Vishnevetsky, MD, MPH. The registered enrollment target is 20 participants, below the 801-participant average among 5 other Optic Neuritis trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06453694, a Phase 2 study of Optic Neuritis, is actively recruiting participants, sponsored by Anastasia Vishnevetsky, MD, MPH.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this pilot clinical trial is to test efgartigimod alfa against placebo in adults with first-time optic neuritis (optic nerve inflammation). The main questions it aims to answer are: * Is it feasible to use efgartigimod alfa for optic neuritis? * Is it feasible to run a larger trial testing efgartigimod alfa in optic neuritis? * Does efgartigimod alfa work better than placebo in improving how quickly and how much vision returns? Participants will: * have their vision and blood tested * be asked questions about their vision * will receive standard of care treatment with steroids regardless of whether they are receiving efgartigimod alfa or not * will have periodic visits over 6 months
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Efgartigimod Alfa
Study Locations (2)
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-08-12 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06453694
The ClinicalTrials.gov registry entry for NCT06453694 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 801-participant average among 5 other Optic Neuritis trials with a reported enrollment target (98% lower). The listed sponsor is Anastasia Vishnevetsky, MD, MPH, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Optic Neuritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06453694 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06453694 about?
NCT06453694 is a clinical study titled "Efgartigimod for the Treatment of Acute Optic Neuritis". The goal of this pilot clinical trial is to test efgartigimod alfa against placebo in adults with first-time optic neuritis (optic nerve inflammation). The main questions it aims to answer are: * Is it feasible to use efgartigimod alfa for optic neuritis? * Is it feasible to run a larger trial test...
What is the current status of trial NCT06453694?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-08-12. Estimated completion is 2027-07.
What conditions does trial NCT06453694 study?
This clinical trial studies the following conditions: Optic Neuritis.
What interventions are being tested in trial NCT06453694?
The interventions under investigation include: Placebo (DRUG), Efgartigimod Alfa (DRUG).
Who is sponsoring clinical trial NCT06453694?
This trial is sponsored by Anastasia Vishnevetsky, MD, MPH, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06453694 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Optic Neuritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
RECRUITING · Phase 2
-
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
RECRUITING · Phase 3
-
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
ACTIVE NOT RECRUITING
-
Biobank For MS And Other Demyelinating Diseases
ACTIVE NOT RECRUITING
-
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.